Browse by intervention

Psyllium: what it changed, and what it did not

One intervention, every measured benefit and result that did not improve in Issue 01. See who it moved for, where it stayed neutral or went the other way, and the next hypothesis Phoenix can validate.

Research issue
Issue 01
Data through
2026-08-09
Evidence map version
v1.1.0
Explore the evidence Get the Evidence Map

How to read this

Phoenix research is longitudinal and observational: we follow real APOE4 carriers over time and compare each member with their own earlier self, with no placebo group, no randomisation, and members choosing their own interventions.

That means these are strong signals pointing at what to test next, not proof of cause. Most nutrition, supplement and lifestyle research you read online has exactly the same design. The difference is that we say so, and we show you the confounders.

Read the full methods and limits

What the Phoenix community is measuring

Browse exact outcomes and interventions. Each result keeps its source, measurement rule and audit record beside the claim.

Get the PDFJoin Phoenix in 7 minutes Open inside Phoenix

Psyllium evidence dossier

Evidence collected through 2026-08-09.

Collecting evidence

No answer yet: Psyllium

Psyllium is being tracked against LDL cholesterol, but Phoenix has not yet published a ranked result for this exact question.

Every carrier who logs a dated start and a repeat test moves this page closer to an answer, including you.

Topic-specific updates about Psyllium · No spam

Audit history

These historical records remain beside the current evidence so you can see why their status changed.

LDL cholesterol

Psyllium

!Record under review

LDL cholesterol moved from 263 to 78 mg/dL in 70 days, but an undated ezetimibe entry may be the real actor.

Selected member cases

  1. Fiber Surprise · APOE4/4 · female · age 50-59

    263 → 78 mg/dL · -70.3% · 70 days

    What else changed: nearby starts included ezetimibe start date unknown.

    Next study: Psyllium and ezetimibe both have human LDL evidence, but the Phoenix case cannot assign the observed fall while the ezetimibe start is undated.

1 selected member case · not a response rate

Logged members
1
Members with repeats
1
Observations
1
Measurements
2
Sources and context

Members with a logged psyllium start and repeat LDL result; this case remains disputed because an ezetimibe start is undated.

  • report-lines-248-343, reviewed by independent verifier

1 selected case shown with this evidence.

Not yet measured

Psyllium and ezetimibe both have human LDL evidence, but the Phoenix case cannot assign the observed fall while the ezetimibe start is undated.

How to test it

Baseline
Record LDL cholesterol before every dated intervention start.
Duration
84 days
Adherence
Track psyllium and ezetimibe separately throughout the window.
Retest
Repeat LDL cholesterol after 12 weeks.
Falsifier
The dated combination does not outperform each intervention tracked separately.
Eligible-member target
40 members

This result is under review: The case stays visible but is excluded from active ranks until every start is dated.

Keep the map

Take every result into your next experiment.

Get the Issue 01 Evidence Map by email. It groups the same evidence by outcome and by intervention, including what worked, what did not, and what Phoenix wants to test next.

Instant PDF · Issue 02 lands in your inbox the day it publishes · No spam

Turn evidence into your next test

Magnesium and homocysteine is 7 members from an answer.

Forty carriers with a dated start and a repeat blood test close it. Creatine, vitamin D3 and B12 sit further back. Your next blood test is somebody else's answer, and theirs is yours.

Take the 7-minute assessment